Proteomics and immunohistochemistry identify loss of nucleophosmin (B23) expression in bladder transitional cell carcinomas

Proteomics and immunohistochemistry identify loss of nucleophosmin (B23) expression in bladder transitional cell carcinomas

Bibliografiska uppgifter
Huvudupphovsmän:	Ahmad, M, Catto, J, Azzouzi, A, Cross, S, Feeley, K, Eaton, C, Meuth, M, Hamdy, F, Rehman, I
Materialtyp:	Journal article
Språk:	English
Publicerad:	2003

Liknande verk

Proteomic analysis of voided urine following prostatic massage reveals tumour specific alterations
av: Rehman, I, et al.
Publicerad: (2004)

Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study.
av: Rehman, I, et al.
Publicerad: (2004)

Tissue microarray immunohistochemistry and cluster analysis confirms the validity of candidate proteins in prostate cancer identified by proteomic analysis of urine
av: Rehman, I, et al.
Publicerad: (2005)

A gene promoter hypermethylation panel to detect transitional cell carcinoma of the bladder
av: Yates, DR, et al.
Publicerad: (2006)

Genetic instability and transitional cell carcinoma of the bladder.
av: Catto, J, et al.
Publicerad: (2004)

Calgizzarin (S100A11) immunostaining pattern is altered in prostate cancer suggesting a role in tumourigenesis
av: Rehman, I, et al.
Publicerad: (2003)

Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma.
av: Catto, J, et al.
Publicerad: (2005)

Promoter hypermethylation identifies progression risk in bladder cancer.
av: Yates, DR, et al.
Publicerad: (2007)

The use of proteomics in urological research
av: Rehman, I, et al.
Publicerad: (2005)

Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls.
av: Yates, DR, et al.
Publicerad: (2006)

Comparing gene promoter methylation frequencies in urine from patients with bladder cancer with urine from non-cancerous young and elderly control patients
av: Yates, DR, et al.
Publicerad: (2005)

FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.
av: van Oers, J, et al.
Publicerad: (2009)

Clinically localised prostate cancer is microsatellite stable.
av: Azzouzi, A, et al.
Publicerad: (2007)

Distinct patterns of microsatellite instability are seen in tumours of the urinary tract.
av: Catto, J, et al.
Publicerad: (2003)

Loss of intercellular expression of beta-dystroglycan is a common event in prostate cancer and is significantly associated with loss of differentiation
av: Cross, S, et al.
Publicerad: (2005)

A single center analysis of nucleophosmin in acute myeloid leukemia: value of combining immunohistochemistry with molecular mutation analysis
av: Carolien M. Woolthuis, et al.
Publicerad: (2013-10-01)

Itraq-facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with progression
av: Rehman, I, et al.
Publicerad: (2008)

iTRAQ-facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with progression.
av: Glen, A, et al.
Publicerad: (2008)

Phosphorylation-dependent migration of retinoblastoma protein into the nucleolus triggered by binding to nucleophosmin/B23.
av: Takemura, M, et al.
Publicerad: (2002)

Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma.
av: Dhawan, D, et al.
Publicerad: (2006)

Involvement of nucleophosmin (NPM1/B23) in assembly of infectious HPV16 capsids
av: Patricia M. Day, et al.
Publicerad: (2015-12-01)

Development of a prognostic marker panel in bladder cancer using aberrant promoter methylation
av: Catto, J, et al.
Publicerad: (2007)

Aberrant promoter methylation in pre-malignant and invasive tumours of the urinary bladder
av: Yates, D, et al.
Publicerad: (2005)

Urinary Bladder Xanthoma – Is Immunohistochemistry Necessary?
av: M. Raghavendran, et al.
Publicerad: (2016-09-01)

DNA promoter methylation in urothelial cancer: a feature of the invasive phenotype and a novel therapeutic target
av: Catto, J, et al.
Publicerad: (2006)

Differential expression of hMLH1 and hMSH2 is related to bladder cancer grade, stage and prognosis but not microsatellite instability.
av: Catto, J, et al.
Publicerad: (2003)

Prostate cancer proteomics: The urgent need for clinically validated biomarkers
av: Evans, C, et al.
Publicerad: (2009)

Gli1 appears to be constitutively expressed in the lumenal epithelial cells of the prostate but not in the basal cell layer or the mesenchyme
av: Spencer, A, et al.
Publicerad: (2004)

Artificial intelligence in predicting bladder cancer outcome: a comparison of neuro-fuzzy modeling and artificial neural networks.
av: Catto, J, et al.
Publicerad: (2003)

Nucleophosmin 1 expression in acute myeloid leukemia
av: Mohammad Davoudi, et al.
Publicerad: (2015-10-01)

Nucleophosmin 1 expression in acute myeloid leukemia
av: Mohammad Davoudi, et al.
Publicerad: (2015-09-01)

Promoter hyper-methylation of calcium binding proteins S100A6 and S100A2 in human prostate cancer.
av: Rehman, I, et al.
Publicerad: (2005)

Epigenetic changes in urothelial cancer: A feature of the invasive phenotype and a novel therapeutic target
av: Catto, J, et al.
Publicerad: (2006)

NSC348884 cytotoxicity is not mediated by inhibition of nucleophosmin oligomerization
av: Markéta Šašinková, et al.
Publicerad: (2021-01-01)

Microsatellite instability as indicator of MSH2 gene mutation in patients with upper urinary tract transitional cell carcinoma.
av: Roupret, M, et al.
Publicerad: (2004)

Cucurbitacin B inhibits human breast cancer cell proliferation through disruption of microtubule polymerization and nucleophosmin/B23 translocation
av: Duangmano Suwit, et al.
Publicerad: (2012-10-01)

Microsatellite instability as predictor of survival in patients with invasive upper urinary tract transitional cell carcinoma.
av: Rouprêt, M, et al.
Publicerad: (2005)

Dysregulated expression of S100A11 (calgizzarin) in prostate cancer and precursor lesions.
av: Rehman, I, et al.
Publicerad: (2004)

Targeting chemotherapy to advanced bladder cancer patients most likely to benefit.
av: Catto, J, et al.
Publicerad: (2010)

Nucleophosmin phosphorylation by v-cyclin-CDK6 controls KSHV latency.
av: Grzegorz Sarek, et al.
Publicerad: (2010-03-01)